The 3-Month Panel: What Your Clinician Is Actually Looking For

The three-month panel exists because of red blood cells. Testosterone's effect on erythropoiesis becomes evident at three months and peaks at nine to twelve.[1] Before three months there is often nothing to see; by three months there is. The Endocrine Society's monitoring standard asks clinicians to measure serum testosterone and hematocrit and to evaluate symptoms, adverse effects and compliance during the first year of therapy.[2]

It is a safety review with a number attached, not a report card.

The four things on the list

The guideline's standardised monitoring plan names them directly.[2]

Serum testosterone. Checked against a target the guideline sets explicitly: mid-normal range. Not the top of the range, and not "as high as tolerated."

Hematocrit. The reason for the timing. Elevated hematocrit is also listed among the conditions under which testosterone therapy should not be started at all, which tells you how the guideline weighs it.[2]

Symptoms and adverse effects. The subjective side, reviewed formally rather than left to whether you happen to mention something.

Compliance. Whether the therapy is actually being taken as prescribed. This sits on the guideline's list, not as an afterthought — an apparent non-response is sometimes an application problem.

Prostate cancer risk assessment is also part of first-year monitoring.[2]

Why "mid-normal" and not higher

The guideline suggests aiming at mid-normal testosterone concentrations during treatment with any of the approved formulations, taking into account patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden and cost.[2]

Higher is not a better outcome by this standard. The risks the monitoring plan tracks — hematocrit above all — scale in the wrong direction, and no trial evidence establishes a benefit to chasing the upper end. A man whose result comes back mid-range and who asks for a dose increase is asking to move away from the guideline's target, not toward it.

What the panel will not tell you

It will not tell you whether the treatment is doing what you hoped, because at three months several effects are still in progress.

Body composition is only just starting: fat mass, lean mass and strength change at twelve to sixteen weeks and stabilise between six and twelve months.[1] Bone effects are detectable at six months and continue for at least three years.[1] Lipids reach maximum somewhere between six and twelve months.[1]

The effects that have finished are the fast ones. Sexual interest plateaus at six weeks with no further increments expected.[1] If libido has not responded by now, the three-month review is the right place to raise it rather than wait — and worth reading alongside what the trials actually found on how long TRT takes to work.

The safety finding that belongs in this conversation

TRAVERSE's fracture sub-study is the one result most often reported backwards, so it is worth stating precisely. Among men on testosterone, clinical fractures occurred in 3.50% versus 2.46% on placebo — a hazard ratio of 1.43.[3] More fractures on treatment, not fewer.

It did not change the trial's primary cardiovascular conclusion, which found testosterone non-inferior to placebo for major adverse cardiac events.[4] But it is a safety signal in a population that is often being treated partly with bone in mind, and it belongs in a monitoring discussion honestly rather than as an afterthought. Starting TRT after 50 covers what it means for older men specifically.

Frequently asked questions

What if my hematocrit is up? That is a conversation with your prescriber about dose, frequency, or pausing. It is a monitored parameter precisely because it is expected to move and sometimes needs acting on.

My testosterone came back mid-range but I still feel flat. What now? Being at target rules out under-dosing as the explanation, which is genuinely useful information. It points the review toward the other common causes of the same symptoms — sleep, thyroid, mood, alcohol, medication — several of which are covered in this hub, including sleep and fatigue.

How often after this? The guideline frames monitoring across the first year, with prostate cancer risk assessment included in that period.[2] The specific cadence after three months is set by your clinician against your results.

Does the draw need to be fasting and morning like the diagnostic one? The fasting morning requirement is specified for the diagnostic measurements.[2] For monitoring, timing is set relative to your dosing schedule so the result is interpretable — ask your clinician when to draw relative to your last application.

Coming to the review prepared

Bring the baseline you wrote down at the start, and the specific thing you most wanted treatment to change. The panel supplies the safety half of the picture; you supply the other half, and it is much more useful written down than recalled.

Keen connects you with a licensed clinical team for a telehealth consultation and lab review. If your testosterone is clinically low, treatment is Keen Testosterone Spray Rx — a once-daily topical spray powered by Hypospray® transdermal delivery.

Related reading: your first month on TRT and the TRAVERSE trial.

References

4 sources

1. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685. doi:10.1530/EJE-11-0221 · PMID 21753068
2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364
3. Snyder PJ, Bauer DC, Ellenberg SS, et al. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203–211. doi:10.1056/NEJMoa2308836 · PMID 38231621
4. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322